Drug General Information
Drug ID	D06HBT
Former ID	DNCL001812
Drug Name	LT-1951
Indication	Coronary artery disease [ICD9: 410-414, 429.2; ICD10:I20-I25]		Phase 1/2	[521773]
Company	Lumen Therapeutics
Structure		Download 2D MOL
Formula	C54H110N36O10
PubChem Compound ID	25077438
Target and Pathway
Target(s)	Nitric oxide synthase, inducible	Target Info	Modulator	[526624]
BioCyc Pathway	Citrulline-nitric oxide cycle
KEGG Pathway	Arginine biosynthesis
	Arginine and proline metabolism
	Metabolic pathways
	Calcium signaling pathway
	HIF-1 signaling pathway
	Peroxisome
	Salmonella infection
	Pertussis
	Leishmaniasis
	Chagas disease (American trypanosomiasis)
	Toxoplasmosis
	Amoebiasis
	Tuberculosis
	Pathways in cancer
	Small cell lung cancer
NetPath Pathway	IL1 Signaling Pathway
	IL2 Signaling Pathway
Pathway Interaction Database	IL12-mediated signaling events
	Alpha9 beta1 integrin signaling events
	ATF-2 transcription factor network
	IL23-mediated signaling events
	Signaling mediated by p38-alpha and p38-beta
	HIF-1-alpha transcription factor network
Reactome	ROS production in response to bacteria
	Nitric oxide stimulates guanylate cyclase
WikiPathways	Type II interferon signaling (IFNG)
	Spinal Cord Injury
	AGE/RAGE pathway
	Effects of Nitric Oxide
References
Ref 521773	ClinicalTrials.gov (NCT00264706) PolyArginine Treated vEiN grafTs (PATENT). U.S. National Institutes of Health.
Ref 526624	Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14. Epub 2003 May 12.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.